186 related articles for article (PubMed ID: 34480729)
21. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
Sato A; Imai Y; Uchiya H; Uchida Y; Nakazawa M; Sugawara K; Nakayama N; Mochida S
Intern Med; 2022 Aug; 61(15):2301-2305. PubMed ID: 35283380
[TBL] [Abstract][Full Text] [Related]
22. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.
Wu J; Wu J; Li S; Luo M; Zeng Z; Li Y; Fu Y; Li H; Liu D; Ou X; Lin Z; Wei S; Yan M
Biosci Trends; 2024 Mar; 18(1):42-48. PubMed ID: 38325823
[TBL] [Abstract][Full Text] [Related]
23. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
24. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
Wang K; Wang H; Lv Y; Liu H; Liu J; Zhang Y
Ann Palliat Med; 2021 Jan; 10(1):803-809. PubMed ID: 33545802
[TBL] [Abstract][Full Text] [Related]
25. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
26. [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
Mukai R; Wada H; Tomimaru Y; Hama N; Kawamoto K; Kobayashi S; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1813-5. PubMed ID: 24393931
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(10):611-621. PubMed ID: 34139691
[TBL] [Abstract][Full Text] [Related]
29. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
30. Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
Peng W; Wu Y; Zhang X; Li C; Shen J; Chen W; Li Q; Ma J; Yang Y; Lu W; Liu Z; Sun X; Yang J; Zhou Y; Wen T
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38447209
[No Abstract] [Full Text] [Related]
31. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
32. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.
Takeda H; Nishijima N; Nasu A; Komekado H; Kita R; Kimura T; Kudo M; Osaki Y
Hepatol Res; 2019 May; 49(5):594-599. PubMed ID: 30499247
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1679. PubMed ID: 35822407
[TBL] [Abstract][Full Text] [Related]
34. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.
Yano R; Hirooka M; Nakamura Y; Imai Y; Koizumi Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
Clin J Gastroenterol; 2024 Apr; 17(2):319-326. PubMed ID: 38281290
[TBL] [Abstract][Full Text] [Related]
35. [Surgical Resection of the Lymph Node Metastasis after Liver Resection for Hepatocellular Carcinoma].
Hashimoto Y; Kishimoto T; Nagano S; Murotani M; Shigetsu K; Yoneda N; Morioka T; Kidogami S; Mokutani Y; Hirose H; Yoshioka S; Kawata J; Takeda M; Tamura S; Sasaki Y
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2284-2286. PubMed ID: 33468935
[TBL] [Abstract][Full Text] [Related]
36. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
37. Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma.
Tachiiri T; Nishiofuku H; Maeda S; Sato T; Toyoda S; Matsumoto T; Chanoki Y; Minamiguchi K; Taiji R; Kunichika H; Yamauchi S; Ito T; Marugami N; Tanaka T
Curr Oncol; 2023 May; 30(5):4779-4786. PubMed ID: 37232818
[TBL] [Abstract][Full Text] [Related]
38. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
39. Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization.
Choi SJ; Kim J; Seo J; Kim HS; Lee JM; Park H
Eur Radiol; 2016 Jan; 26(1):225-34. PubMed ID: 25991485
[TBL] [Abstract][Full Text] [Related]
40. Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis.
Komatsu S; Yano Y; Sofue K; Kido M; Tanaka M; Kuramitsu K; Awazu M; Gon H; Yamamoto A; Yanagimoto H; Toyama H; Kodama Y; Murakami T; Fukumoto T
HPB (Oxford); 2020 Oct; 22(10):1450-1456. PubMed ID: 32238302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
